HRTX · Heron Therapeutics Inc
United States · RS rating 19 · As of 2026-10-14
| Price | 0.36 USD |
|---|---|
| 1-day change | -7.2% |
| RS rating (overall / 1M / 3M / 12M) | 19 / 96 / 15 / 8 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 22 / 28 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +80.0% |
| Sales growth Q/Q | +6.2% |
| Distance from 52-week high | +75.7% |
| Market cap (USD) | $188.5M |